Abstract: The invention relates to the use of lornoxicam or analogues thereof which inhibit cyclo-oxygenase 1 and cyclo-oxygenase 2 (COX 1 and COX 2), cannot penetrate the blood-brain barrier under physiological conditions, and reduce the prostaglandin E2-induced induction of the amyloid-precursor-protein (APP), for producing a pharmaceutical composition for the treatment or prevention of Alzheimer's disease or arteriosclerosis.

Abstract: The invention relates to the novel therapeutically valuable enantiomer-pure [3a?,8b?]-1,2,3a,4,8b-hexahydropyrrolocyclopentapyridine derivatives of the general formula (I), wherein Z is a single bond or CH2, R1 represents hydrogen or a straight-chain or branched, optionally unsaturated lower alkyl group which may be perfluorated, R2 and R3 independently represent hydrogen, a straight-chain or branched, optionally unsaturated lower alkyl group which may be perfluorated, lower alkoxy, lower alkylthio or halogen, and X and Y alternatively represent CH or N. The invention also relates to the pharmaceutical salts thereof, to a method for their production and to their use.

Abstract: Methods of treating and/or preventing arteriosclerosis are disclosed. In certain methods, a composition containing at least one lornoxicam or lornoxicam analogue that inhibits cyclooxygenase 1 and cyclooxygenase 2 (COX 1 and COX 2), cannot cross the blood/brain barrier under physiological conditions, and reduces the prostaglandin E2-induced induction of the amyloid precursor protein (APP) is administered to a subject to treat and/or prevent arteriosclerosis in the subject.

Abstract: The invention relates to the use of lornoxicam or analogues thereof which inhibit cyclo-oxygenase 1 and cyclo-oxygenase 2 (COX 1 and COX 2), cannot penetrate the blood-brain barrier under physiological conditions, and reduce the prostaglandin E2-induced induction of the amyloid-precursor-protein (APP), for producing a pharmaceutical composition for the treatment or prevention of Alzheimer's disease or arteriosclerosis.

Abstract: Thienothiazine derivatives of the formula ##STR1## are provided. These derivatives are useful for the treatment of inflammation and pain.

Abstract: Thermally split zirconium silicate is produced such that the crystalline zirconium dioxide embedded in an amorphous silica phase exhibits an average grain or particle size (d.sub.50 value) in a range of 0.5 .mu.m to 3.0 .mu.m and a specific surface (BET) in a range of 3 to 15 m.sup.2 /g. The zirconium dioxide produced by this method is particularly suited for the production of zirconium silicate pigments with improved color characteristics. The thermally split zirconium silicate is also particularly well suited for processes used in the obtention of zirconium dioxide. The method of producing the thermally split zirconium silicate includes melting zirconium silicate in an induction melting furnace and cooling off a free falling stream of melt by blowing on it with a gas and/or spraying it with water.

Abstract: Thienothiazine derivatives of the formula ##STR1## in which X denotes a single bond, a straight chain or branched carbon chain having 1-12 C-atoms in the chain, it being possible for this chain to contain one or more double or triple bonds and/or two or more heteroatoms, Y denotes a single bond, and R denotes a monocyclic or polycyclic, optionally partly hydrogenated aryl, heteroaryl, arlyoxy, arylaza, heteroarylaza, arylthio or heteroarylthio radical which can optionally be substituted by lower alkyl, mono- or poyhalogenated lower alkyl, perfluorinated lower alkyl, alkoxy or halogen, and their use.

Abstract: A method is disclosed for the semi-continuous melting of ceramic material by means of inductive melting in high-frequency and medium-frequency induction melting furnaces whose melting coil surrounds a sintering crust crucible and contains a run-out channel. In the method, melt is periodically run out and material to be melted is supplied to the crucible so as to replace the material removed preferably so as to maintain a constant level. An intensively cooled channel is used as a run-out device. For the melt broaching, the melt nose is grasped from below by way of an automatically controllable broaching lance of a broaching device and raised. The broaching lance is then advanced between the bottom of the channel and the solidified melt until the sintering crust is pierced. The method permits a reliable and economic management of the process and the maintenance of the quality of the melted products.

Abstract: A method is disclosed for the semi-continuous melting of ceramic material by means of inductive melting in high-frequency and medium-frequency induction melting furnaces whose melting coil surrounds a sintering crust crucible and contains a run-out channel. In tile method, melt is periodically run out and material to be melted is supplied to the crucible so as to replace the material removed preferably so as to maintain a constant level. An intensively cooled channel is used as a run-out device. For the melt broaching, the melt nose is grasped from below by way of an automatically controllable broaching lance of a broaching device and raised. The broaching lance is then advanced between the bottom of the channel and the solidified melt until the sintering crust is pierced. The method permits a reliable and economic management of the process and the maintenance of the quality of the melted products.

Abstract: There are described novel compounds of the general formula ##STR1## in which R in position 3 or 4 is hydrogen, methyl, chlorine or bromine and R.sup.2 is C.sub.1 -C.sub.10 -alkyl, C.sub.3 -C.sub.7 -cycloalkyl or benzyl, and the pharmaceutically acceptable addition salts thereof with weak organic acids as well as a process for the preparation thereof.The compounds of formula (I) are inhibitors of thromboxane synthetase.

Abstract: Thermally split zirconium silicate is produced such that the crystalline zirconium dioxide embedded in an amorphous silica phase exhibits an average grain or particle size (d.sub.50 value) in a range of 0.5 .mu.m to 3.0 .mu.m and a specific surface area (BET) in a range of 3 to 15 m.sup.2 /g when the silica is removed by leaching. The zirconium dioxide produced by this method is particularly suited for the production of zirconium silicate pigments with improved color characteristics. The thermally split zirconium silicate is also particularly well suited for processes used in the obtention of zirconium dioxide. The method of producing the thermally split zirconium silicate includes melting zirconium silicate in an induction melting furnace and cooling off a free falling stream of melt by blowing on it with a gas and/or spraying it with water.

Abstract: A monoclinic zirconium dioxide with an SiO.sub.2 content below 1.0% by weight is provided which is characterized by dendrite-shaped particles with an average grain size (d.sub.50 value) in a range of 0.5 .mu.m to 3.0 .mu.m and a specific surface (BET) in a range of 3 to 15 m.sup.2 /g. This zirconium dioxide is produced by thermally splitting zirconium silicate in a high-frequency- or medium-frequency induction melting furnace with sintering crust crucible, quenching the melt by blowing on a stream of melt with air and/or spraying it with water and leaching out the thermally split zirconium silicate with concentrated alkali lye at 100.degree. 200.degree. C. The zirconium dioxide of the invention provides a material with improved suitability for the production of zirconium silicate pigments of the host lattice type and inclusion type so as to provide for more color-intensive pigments.

Abstract: Novel imidazole-5-carboxylic acid acylals of the general formula ##STR1## in which R.sub.1 denotes an optionally unsaturated, straight-chain alkyl group having 1-6 carbon atoms, R.sub.2 denotes hydrogen, chlorine, bromine, iodine or CF.sub.3 and R.sub.3 denotes C.sub.1 -C.sub.10 -alkyl, C.sub.3 -C.sub.7 -cycloalkyl or benzyl, and their pharmaceutically tolerable salts.

Abstract: A method is disclosed for the semi-continuous melting of ceramic material by means of inductive melting in high-frequency and medium-frequency induction melting furnaces whose melting coil surrounds a sintering crust crucible and contains a run-out channel. In the method, melt is periodically run out and material to be melted is supplied to the crucible so as to replace the material removed preferably so as to maintain a constant level. An intensively cooled channel is used as a run-out device. For the melt broaching, the melt nose is grasped from below by way of an automatically controllable broaching lance of a broaching device and raised. The broaching lance is then advanced between the bottom of the channel and the solidified melt until the sintering crust is pierced. The method permits a reliable and economic management of the process and the maintenance of the quality of the melted products.

Abstract: Tetrazole derivatives of the formula ##STR1## in which R.sub.1 denotes a saturated or unsaturated, straight-chain or branched (C.sub.1 -C.sub.6) alkyl radical and R.sub.2 denotes methyl or ethyl, and their pharmaceutically usable salts.

Abstract: Thienyloxyalkylamine derivatives of the general formula: ##STR1## wherein --O--CH.sub.2 --CH.sub.2 --NR.sub.2 R.sub.3 is in position 4 or 5 of the thiophene ring;R.sub.1 is hydrogen, halogen, CF.sub.3, alkyl or alkoxy;R.sub.2 and R.sub.3 are the same or different and are each alkyl, cycloalkyl, alkenyl or alkynyl each having up to 8 C atoms, or NR.sub.2 R.sub.3 is a 5 to 7-membered saturated heterocyclic ring optionally containing a further hetero atom which is oxygen or nitrogen optionally substituted by an alkyl group having 1 to 3 C atoms; andn is an integer of 1 to 5; as well as their acid addition salts, are suitable for treatment of heart rhythm disturbances.

Abstract: Sulphamoylathiophenes of the formula ##STR1## in which Y denotes O or S,A denotes a single bond or a straight-chain or branched alkylene group having 1-5 carbon atoms,R.sub.1 denotes methyl or trifluoromethyl andR.sub.2 denotes hydrogen or a group COOH or COOR.sub.3, in whichR.sub.3 represents (C.sub.1 -C.sub.4)-alkyl,and, in the case in which R.sub.2 denotes a group COOH, their pharmaceutically tolerable salts, a process for their preparation, pharmaceutical preparations which contain these compounds and their use in medicaments as leukotriene antagonists for the treatment of asthma and allergies.

Abstract: Thienopyran derivatives of the general formula ##STR1## in which the radial ##STR2## denotes one of the formulae ##STR3## R denotes hydrogen or a radical --CN, --CHO, --CH.dbd.NOH, --CONH.sub.2 or --COOR.sub.1,R.sub.1 denotes the radical (C.sub.1 -C.sub.4)-alkyl and n denotes an integer 3, 4 or 5, and a process for their preparation, pharmaceutical preparation and their use for the treatment of diseases which can be cured by activation of membrane K.sup.+ channels, such as high blood pressure and asthma.

Abstract: 1-(3-(2-hydroxy-3-alkylaminopropoxy)-2-thienyl)-3-phenyl-1-propanones represented by formula (I) ##STR1## wherein R.sub.1 and R.sub.2 each represent a lower alkyl group, and a process for the preparation of the same. The compounds of the present invention are useful in the treatment of cardiac arrhythmias.

Abstract: The invention relates to novel thieno-(3',4'-4,5)imidazo(2,1-b)thiazole derivatives of the formula ##STR1## in which R.sub.1 denotes hydrogen, halogen or CF.sub.3 andR.sub.2 denotes hydrogen or C.sub.1 -C.sub.4 alkyl and, in the case in which R.sub.2 denotes hydrogen, their pharmaceutically utilizable salts, a process for the preparation of these compounds and their use for the treatment of cancer or rheumatoid arthritis caused by a defective immune system.